A Mendelian randomization study suggested a lower risk of prostate cancer associated with SGLT-2 inhibition, potentially related to reductions in prostate-specific antigen (PSA) levels and uridine metabolism [344]. This evidence concerns the gene KLK3 and Familial prostate cancer.